Evidence map›Paper›PMID 40865207›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2025

Brain exposure of the mesenchymal-epithelial transition inhibitor savolitinib in nonhuman primates: A positron emission tomography study.

Peter Johnström, Zsolt Cselényi, Kowser Miah, Aurelija Jucaite, Graeme Scarfe, Miguel A Cortés González, Lars Farde, Christer Halldin, Karthick Vishwanathan, Magnus Schou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Peter JohnströmPET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Stockholm, Sweden; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Zsolt CselényiPET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Stockholm, Sweden; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Kowser MiahClinical Pharmacology & Quantitative Pharmacology, CPSS, AstraZeneca, Boston, Massachusetts.
Aurelija JucaitePET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Stockholm, Sweden; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Graeme ScarfeDrug Metabolism and Pharmacokinetics, Oncology R&D, Research & Early Development, AstraZeneca, Cambridge, United Kingdom.
Miguel A Cortés GonzálezDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Lars FardeDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Christer HalldinDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Karthick VishwanathanClinical Pharmacology & Quantitative Pharmacology, CPSS, AstraZeneca, Boston, Massachusetts.
Magnus SchouPET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Stockholm, Sweden; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden. Electronic address: magnus.schou@astrazeneca.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The receptor tyrosine kinase mesenchymal-epithelial transition factor inhibitor savolitinib is currently being evaluated as a treatment in non-small cell lung cancer (NSCLC) in combination with osimertinib. NSCLC patients with epidermal growth factor receptor/anaplastic lymphoma kinase mutations appear to have a high incidence (50%-60%) of brain metastasis; hence, cancer drugs that can efficiently access the brain hold a critical advantage. In this study, savolitinib blood-brain barrier penetration properties were investigated in nonhuman primates using positron emission tomography and intravenous administration of microdoses of [

Indexed as

BrainEpithelial-Mesenchymal TransitionPositron-Emission TomographyAnimalsBlood-Brain BarrierFemaleHumansInjections, IntravenousMacaca fascicularisMacaca mulattaMaleProtein-Tyrosine KinasesPyrazinesTissue DistributionTriazinesTyrosine Kinase Inhibitors1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazineProtein-Tyrosine KinasesPyrazinesTriazinesTyrosine Kinase InhibitorsBrain distributionPositron emission tomographySavolitinib

Identifiers

PMID40865207
PMCPMC12597574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.